Cigna Group stock: Piper Sandler cuts target to 360 dollars

Piper Sandler lowered its price target for Cigna Group on Thursday, November 12, while keeping an Overweight rating on the shares. The analyst cited pressure from a contracting rebate pool and weaker commercial coverage of GLP-1 medicines, according to Investing.com.

Cigna Group stock traded at 268.80 euros on Lang & Schwarz at 13:14 CET on Friday, November 13, 2026, 0.22 percent above the Xetra close of Thursday, November 12.

Pharmacy Risks Shape The Outlook

Piper Sandler expects earnings from Cigna's pharmacy benefit services business to decline by a high-single-digit percentage in calendar 2027, with additional margin erosion. The firm said it was optimistic, but not confident, that the business would reach a trough in 2027.

The revised target reflects an unchanged 10-times multiple applied to lower 2028 adjusted earnings estimates. Piper Sandler's Overweight view assumes that Cigna can preserve the economics of its business through the Signature transition, while its valuation still assigns meaningful worth to the pharmacy benefit services operation.

Strong Quarter, Mixed Signals

Cigna reported adjusted third-quarter earnings of 7.98 dollars per share and revenue of 73.7 billion dollars, beating Wall Street expectations of 7.52 dollars per share and 72.65 billion dollars, respectively. Cigna Healthcare led the earnings beat, with pretax adjusted operating income 105.1 million dollars above consensus, according to the cited report.

Following the quarter, management lifted the full-year 2026 adjusted earnings outlook to at least 30.60 dollars per share. The company also set a 2027 adjusted earnings floor of 33.00 dollars per share, which Piper Sandler said was below the previous consensus by 0.51 dollars.

The split between near-term delivery and later concerns is central for investors. Stronger third-quarter operations and the higher 2026 earnings floor support the current earnings profile, while pharmacy pricing, rebate economics, GLP-1 coverage and the planned exit from the ACA exchange business create uncertainty around 2027 profitability.

Analysts Take Different Paths

Analyst sentiment is not uniform. Bernstein SocGen Group raised its price target from 387 dollars to 390 dollars and maintained an Outperform rating, citing Cigna's 2027 growth outlook and an Investor Day framework calling for growth above 10 percent. Piper Sandler's lower target shows that the same long-term opportunity is being weighed against more immediate pressure in pharmacy benefits.

For the stock, the next test is whether Cigna can convert the higher 2026 earnings base into durable growth while protecting margins during the Signature transition. The company's execution on pharmacy-benefit economics and the ACA exit will remain important indicators for the longer-term valuation.

Broader investor sentiment can be followed through the S&P 500 market overview.

More news and analyses on Cigna Group stock.